By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

YEAR FOUNDED:

August 5, 2013

LEADERSHIP:

Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen

CEO and Co-founder: Hans Bishop

JOBS:

Please click here for job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


FOLLOW JUNO:



Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO
 



Industry
Biotechnology






Company News
Investors Beware: Thin CAR-T Data Could Make or Break Juno (JUNO) and Kite Pharma (KITE) 9/22/2016 7:05:48 AM
Juno (JUNO) Spends Big Bucks on R&D, Even Though Approval Won't Come Until 2018 9/22/2016 7:00:17 AM
Despite Trial Deaths, Juno (JUNO) Could Still Be the CAR-T Leader 9/13/2016 7:39:16 AM
Juno (JUNO), Nektar Therapeutics (NKTR) CEOs Sold $1 Million of Stock Before Labor Day 9/9/2016 6:04:31 AM
Juno (JUNO) Co-Founder & Director Richard Klausner, M.D., To Keynote Governor’s Life Sciences Summit & Annual Meeting 9/8/2016 1:27:17 PM
Juno (JUNO) Surges as Small Cancer Study is Hailed a Success, Shows Promise for Other Drugs 9/8/2016 5:55:35 AM
Juno (JUNO) To Present At September 2016 Investor Conferences 9/7/2016 12:52:59 PM
Juno (JUNO) Facing Class Action Lawsuit Following Patient Deaths 8/17/2016 6:57:58 AM
Juno (JUNO) Reports Second Quarter 2016 Financial Results 8/5/2016 10:51:33 AM
Juno (JUNO) Announces Multiple Myeloma Partnership With Memorial Sloan-Kettering Cancer Center And Eureka Therapeutics For Developing CAR T Cell Immunotherapy Against Multiple Novel Targets 8/5/2016 10:17:53 AM
12345678910...
//-->